Haemonetics Co. (NYSE:HAE) CFO William P. Mr. Burke sold 13,056 shares of the business’s stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $114.33, for a total transaction of $1,492,692.48. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
William P. Mr. Burke also recently made the following trade(s):
- On Thursday, October 25th, William P. Mr. Burke sold 841 shares of Haemonetics stock. The stock was sold at an average price of $46.76, for a total transaction of $39,325.16.
NYSE HAE traded down $3.47 during trading hours on Friday, hitting $111.61. 667,800 shares of the company’s stock traded hands, compared to its average volume of 561,608. Haemonetics Co. has a 52-week low of $53.74 and a 52-week high of $117.56. The stock has a market cap of $5.62 billion, a PE ratio of 59.68, a P/E/G ratio of 3.52 and a beta of 1.09. The company has a current ratio of 2.92, a quick ratio of 1.94 and a debt-to-equity ratio of 0.47.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. CIBC Asset Management Inc purchased a new stake in Haemonetics during the 3rd quarter valued at about $219,000. Welch & Forbes LLC purchased a new stake in Haemonetics during the 3rd quarter valued at about $229,000. Oakbrook Investments LLC purchased a new stake in Haemonetics during the 3rd quarter valued at about $229,000. Wealth Alliance Advisory Group LLC purchased a new stake in Haemonetics during the 3rd quarter valued at about $229,000. Finally, CIBC World Markets Inc. purchased a new stake in Haemonetics during the 3rd quarter valued at about $233,000. 96.44% of the stock is owned by institutional investors.
A number of research firms have recently commented on HAE. Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 target price for the company in a research note on Friday, October 12th. Barrington Research reissued a “buy” rating and set a $127.00 target price on shares of Haemonetics in a research note on Friday, October 5th. Jefferies Financial Group reissued a “buy” rating and set a $125.00 target price on shares of Haemonetics in a research note on Tuesday, August 7th. TheStreet cut shares of Haemonetics from a “b” rating to a “c+” rating in a research note on Monday, August 20th. Finally, Morgan Stanley boosted their target price on shares of Haemonetics from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 8th. One analyst has rated the stock with a hold rating, four have given a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $113.20.
COPYRIGHT VIOLATION NOTICE: “Haemonetics Co. (HAE) CFO William P. Mr. Burke Sells 13,056 Shares” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.wkrb13.com/2018/11/10/haemonetics-co-hae-cfo-william-p-mr-burke-sells-13056-shares.html.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Read More: Determine Your Level of Risk Tolerance
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.